PMC:7784828 / 17040-18421 JSONTXT

{"project":"LitCovid-sentences","denotations":[{"id":"T141","span":{"begin":0,"end":157},"obj":"Sentence"},{"id":"T142","span":{"begin":158,"end":316},"obj":"Sentence"},{"id":"T143","span":{"begin":317,"end":466},"obj":"Sentence"},{"id":"T144","span":{"begin":467,"end":731},"obj":"Sentence"},{"id":"T145","span":{"begin":732,"end":887},"obj":"Sentence"},{"id":"T146","span":{"begin":888,"end":1090},"obj":"Sentence"},{"id":"T147","span":{"begin":1091,"end":1189},"obj":"Sentence"},{"id":"T148","span":{"begin":1190,"end":1381},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Very recently, an unprecedented effort, as ever in the history, has been made to avert the COVID-19 pandemic by the National Institutes of Health (NIH) [47]. The NIH in collaboration with major drug companies and funders has announced a plan to conduct clinical trials employing drugs and vaccines to treat COVID-19. Priorities have been designated for testing and development of selected drugs/vaccines to avoid duplication and wastage of time, money and resources. The partnership called Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) is a collaborative network of NIH, government agencies in the U.S, pharma/biotech companies, academia and nonprofit Foundations of the National Institutes of Health (FNIH). ACTIV is defined as an international strategy to evaluate data on most promising early drug candidates for clinical trials by efficient use of NIH funding. The alliance will also study and analyze the genome of all SARS-CoV-2 strains, and how the virus infects various cell types and patients with different, underlining conditions, ages and genetic makeups. This is what the whole world looks forward to, a global alliance for the benefit of the humankind. Public–private partnerships, adaptive trial designs, and big data offers excellent avenues for innovating drug discovery and design process but face several challenges which must be met [27]."}

{"project":"LitCovid-PubTator","denotations":[{"id":"171","span":{"begin":947,"end":957},"obj":"Species"},{"id":"172","span":{"begin":1016,"end":1024},"obj":"Species"},{"id":"173","span":{"begin":91,"end":99},"obj":"Disease"},{"id":"174","span":{"begin":307,"end":315},"obj":"Disease"},{"id":"175","span":{"begin":503,"end":511},"obj":"Disease"}],"attributes":[{"id":"A171","pred":"tao:has_database_id","subj":"171","obj":"Tax:2697049"},{"id":"A172","pred":"tao:has_database_id","subj":"172","obj":"Tax:9606"},{"id":"A173","pred":"tao:has_database_id","subj":"173","obj":"MESH:C000657245"},{"id":"A174","pred":"tao:has_database_id","subj":"174","obj":"MESH:C000657245"},{"id":"A175","pred":"tao:has_database_id","subj":"175","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Very recently, an unprecedented effort, as ever in the history, has been made to avert the COVID-19 pandemic by the National Institutes of Health (NIH) [47]. The NIH in collaboration with major drug companies and funders has announced a plan to conduct clinical trials employing drugs and vaccines to treat COVID-19. Priorities have been designated for testing and development of selected drugs/vaccines to avoid duplication and wastage of time, money and resources. The partnership called Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) is a collaborative network of NIH, government agencies in the U.S, pharma/biotech companies, academia and nonprofit Foundations of the National Institutes of Health (FNIH). ACTIV is defined as an international strategy to evaluate data on most promising early drug candidates for clinical trials by efficient use of NIH funding. The alliance will also study and analyze the genome of all SARS-CoV-2 strains, and how the virus infects various cell types and patients with different, underlining conditions, ages and genetic makeups. This is what the whole world looks forward to, a global alliance for the benefit of the humankind. Public–private partnerships, adaptive trial designs, and big data offers excellent avenues for innovating drug discovery and design process but face several challenges which must be met [27]."}